OBJECTIVE: To evaluate treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy (POEFRT) with or without chemotherapy. METHODS: Between 1983 and 2006, 35 patients with a pathologically confirmed positive para-aortic node (PAN) or common iliac node (CIN) who underwent a radical hysterectomy with bilateral pelvic lymph node dissection and PAN dissection received POEFRT with (N=23) or without (N=12) chemotherapy. Prognostic factors such as age, stage, size, parametrium invasion, lymphovascular space invasion, nodal station, depth of stromal invasion and use of chemotherapy were analyzed. RESULTS: With a median follow-up of 44 months, the 5-year overall survival (OS), disease-free survival (DFS), distant failure-free survival (DFFS) and loco-regional failure-free survival rates were 51%, 51%, 59% and 93%, respectively. The use of chemotherapy significantly improved the 5-year OS rate (61% vs. 48%, p=0.004), the 5-year DFS rate (54% vs. 38%, p=0.004) and the 5-year DFFS rate (57% vs. 48%, p=0.009). PAN involvement resulted in a compromised 5-year DFS rate (42% vs. 73%, p=0.002) and 5-year DFFS rate (47% vs. 82%, p=0.004) as compared to CIN involvement. Grade 3 or higher hematological toxicity was observed more frequently in patients who received POEFRT combined with chemotherapy as compared to patients who received POEFRT alone (52% vs. 17%, p=0.04). CONCLUSION: The use of POEFRT resulted in an excellent loco-regional control rate. The addition of chemotherapy may improve outcome in patients who have received POEFRT, but with higher manageable toxicity.
OBJECTIVE: To evaluate treatment outcomes and prognostic factors in uterine cervical cancerpatients treated with postoperative extended field radiation therapy (POEFRT) with or without chemotherapy. METHODS: Between 1983 and 2006, 35 patients with a pathologically confirmed positive para-aortic node (PAN) or common iliac node (CIN) who underwent a radical hysterectomy with bilateral pelvic lymph node dissection and PAN dissection received POEFRT with (N=23) or without (N=12) chemotherapy. Prognostic factors such as age, stage, size, parametrium invasion, lymphovascular space invasion, nodal station, depth of stromal invasion and use of chemotherapy were analyzed. RESULTS: With a median follow-up of 44 months, the 5-year overall survival (OS), disease-free survival (DFS), distant failure-free survival (DFFS) and loco-regional failure-free survival rates were 51%, 51%, 59% and 93%, respectively. The use of chemotherapy significantly improved the 5-year OS rate (61% vs. 48%, p=0.004), the 5-year DFS rate (54% vs. 38%, p=0.004) and the 5-year DFFS rate (57% vs. 48%, p=0.009). PAN involvement resulted in a compromised 5-year DFS rate (42% vs. 73%, p=0.002) and 5-year DFFS rate (47% vs. 82%, p=0.004) as compared to CIN involvement. Grade 3 or higher hematological toxicity was observed more frequently in patients who received POEFRT combined with chemotherapy as compared to patients who received POEFRT alone (52% vs. 17%, p=0.04). CONCLUSION: The use of POEFRT resulted in an excellent loco-regional control rate. The addition of chemotherapy may improve outcome in patients who have received POEFRT, but with higher manageable toxicity.
Entities:
Keywords:
Cervix cancer; Chemotherapy; Postoperative extended field radiotherapy
Authors: G Delgado; B N Bundy; W C Fowler; F B Stehman; B Sevin; W T Creasman; F Major; P DiSaia; R Zaino Journal: Gynecol Oncol Date: 1989-12 Impact factor: 5.482
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: B M Sood; P F Timmins; G R Gorla; M Garg; P S Anderson; B Vikram; G L Goldberg Journal: Int J Gynecol Cancer Date: 2002 Sep-Oct Impact factor: 3.437
Authors: Cecelia H Boardman; William E Brady; Don S Dizon; Charles A Kunos; Kathleen N Moore; Kristine M Zanotti; Cara Matthews; Jonathan A Cosin; Carol Aghajanian; Paula M Fracasso Journal: Gynecol Oncol Date: 2018-08-31 Impact factor: 5.482
Authors: Hak Jae Kim; Jin Ho Kim; Sung Whan Ha; Hong-Gyun Wu; Jin Hwa Choi; Kyung-Mi Lee; Seung Wan Kang Journal: J Gynecol Oncol Date: 2012-04-03 Impact factor: 4.401